News
(Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the first patient has been dosed in the pivotal Phase 3 OVATION 3 Study ...
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback